Status:
TERMINATED
Circumferential Vertebral Reconstruction of Osteoporotic Compression Fractures Using a Novel Bipedicular Peek Implant
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Conditions:
Vertebral Compression Fractures
Osteoporotic Vertebral Compression Fractures
Eligibility:
All Genders
50+ years
Phase:
NA
Brief Summary
The RECONSTRUCT study is a multi-center, prospective, single arm, post-market, pilot study to evaluate clinical and radiologic outcome data regarding the use of the Vertebral Implant PEEK (VIP) implan...
Detailed Description
Vertebral compression fractures affect an estimated 1.4 million patients in the world annually and incidence rates rise exponentially with age, especially in women. Outcomes following non-intervention...
Eligibility Criteria
Inclusion
- Age ≥ 50
- Osteoporotic compression fractures of the thoracolumbar spine (T1 -L5)
- Up to three levels can be fractured and treated, but at least one of the three need to be treated with V-STRUT; the level(s) to be treated with study device is at the discretion of the enrolling investigator
- Fracture age of ≤ 12 weeks as indicated by onset of pain or known antecedent traumatic event with corresponding evidence of acuity on MRI (T1 and STIR sequences) or radioisotope bone scan
- ODI ≥ 30/100 at screening visit and VAS ≥ 60 at screening visit
- Failure of conservative management strategies for compression fractures resulting in inadequately controlled pain and/or patient immobility
- Patient has failed non-operative medical therapy as defined by one of the following definitions set forth by the American College of Radiology:
- For a patient rendered nonambulatory as a result of pain from a VCF, pain persisting at a level that prevents ambulation despite 24 hours of analgesic therapy; or
- For a patient with sufficient pain from a VCF such that physical therapy is intolerable, pain persisting at that level despite 24 hours of analgesic therapy; or
- For a patient with pain from a VCF, unacceptable side effects such as excessive sedation, confusion, or constipation as a result of the analgesic therapy necessary to reduce pain to a tolerable level.
- Magerl classification A1.1, A1.2, A1.3, A2.1, A2.2 and A3.1 type fractures: pediculosomatic junction fractures and other fractures involving vertebral pedicles
- Appropriate pedicle diameter to receive 4.5mm, 5.5mm diameter or 6.5mm diameter implants
- ASA \< 4
Exclusion
- Patient clearly improving on conservative treatment
- Any contra-indication or allergy to implant material or cement
- Systemic infection or infection located in the spine
- Any medical condition including but not limited to anemia, coagulation disorders, fibromyalgia, algoneurodystrophy, Paget's disease, uncontrolled diabetes that would preclude the patient from having surgery or would impede the benefit of surgery
- Neurologic signs or symptoms related to the fracture or the impeding pathological fracture
- Any previous surgical treatment (material or cement) in the targeted vertebra
- Less than one third of the original vertebral body height remaining
- Unstable fractures or neoplasms with posterior involvement
- Damages of the posterior wall
- Sclerotic cancellous bone
- Pedicles not large enough to accept V-STRUT© instrumentation and implants
- Pregnancy(women of childbearing potential must have a negative pregnancy test to participate)
- Pre-existing or clinically unstable neurologic deficit
- Spinal canal compromise causing clinical manifestations of cord, neural foramen, or nerve root compression at the level to be treated
- Any physical exam evidence of myelopathy or radiculopathy
- Pain based on clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis (progressive weakness or paralysis)
- Bedbound prior to incident fracture
- Spondylolisthesis \>Grade 1 at target VB
- Any underlying systemic bone disease other than osteoporosis (e.g., osteomalacia, osteogenesis imperfect, Paget's disease, etc.)
- A medical contraindication to spinal surgery and/or general anesthesia, such as coagulopathy and/or taking warfarin (Coumadin) or other anticoagulant or anti-aggregate (anti-platelet agents) on regular basis for coagulopathy (with a threshold for normal being INR≤1.5, PTT within lab normal range, and platelet count \> 100,000)
- Disabling backpain due to causes other than acute fracture
- Severe cardiopulmonary deficiencies
- Any evidence of alcohol or drug abuse
- Uncontrolled psychiatric illness or severe dementia
- Involved in medical litigation including workers' compensation
Key Trial Info
Start Date :
May 10 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 7 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05337696
Start Date
May 10 2022
End Date
March 7 2025
Last Update
July 8 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins
Baltimore, Maryland, United States, 21287
2
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
3
St. Luke's
Bethlehem, Pennsylvania, United States, 18015
4
West Virginia
Morgantown, West Virginia, United States, 26506